[Control status and follow-up of acute attacks in children with bronchial asthma with normal pulmonary ventilation function]. / è‚ºé€šæ°”åŠŸèƒ½æ­£å¸¸çš„å„¿ç«¥æ”¯æ°”ç®¡å“®å–˜æŽ§åˆ¶æƒ å†µåŠæ€¥æ€§å‘ä½œéšè®¿çš„ç ”ç©¶.

OBJECTIVES: To investigate the control status of bronchial asthma (referred to as "asthma") in school-age children with normal pulmonary ventilation function and the occurrence of acute attacks within 1 year of follow-up. METHODS: A retrospective analysis was conducted on clinical data of 327 children aged 6-14 years with bronchial asthma and normal pulmonary ventilation function from April to September 2021. Based on the measured value of one second rate (FEV1/FVC), the children were divided into the ≥80% group (267 cases) and the <80% group (60 cases). The pulmonary ventilation function, asthma control level, and occurrence of acute attacks within 1 year were compared between the two groups. RESULTS: The baseline pulmonary ventilation function in the <80% group was lower than that in the ≥80% group, and the proportion of small airway dysfunction was higher than that in the ≥80% group (P<0.05). After standardized treatment for 1 year, the small airway function indices in the <80% group improved but remained lower than those in the ≥80% group (P<0.05). The rate of incomplete asthma control at baseline was 34.6% (113/327), and the asthma control level in the <80% group was lower than that in the ≥80% group (P<0.05). After standardized treatment for 1 year, the asthma control level in the <80% group remained lower than that in the ≥80% group, and the proportion of acute asthma attacks was higher than that in the ≥80% group (P<0.05). CONCLUSIONS: Approximately one-third of school-age children with asthma still have incomplete asthma control when their pulmonary ventilation function is normal. Among them, children with measured FEV1/FVC<80% have an increased risk of acute asthma attacks and require close follow-up and strengthened asthma management.

Quantity and proliferation rate of mesenchymal stem cells in human cord blood during gestation.

UCB (umbilical cord blood) as a resource of MSCs (mesenchymal stem cells) is widely accepted, but the quantity and characteristics of UCB-MSCs from different gestational ages have not been well studied. We have quantified the number of MSCs in UCB at different gestational ages using a multi-colour flowcytometer and compared the cell proliferation rates of these UCB-MSCs. Defining MSCs as CD44+/CD105+/CD34-/CD45 population, their numbers declined in the UCB at the gestational age. Proliferation rates were significantly higher in UCB before term than at full term. Non-full term UCB samples may be a better source of MSCs.

[The relationship between expression of macrophage migration inhibitory factor and prognosis of breast cancer].

OBJECTIVE: To investigate the expression of macrophage migration inhibitory factor (MIF) in breast cancer and to analyze the relationship between MIF expression and clinicopathological features, tumor microvessel density (MVD), and prognosis. METHOD: The expression of MIF in 121 samples of breast cancer, 20 samples of breast benign tumors, and 20 samples of normal breast tissues were examined by tissue microarray using immunohistochemistry. The values of MVD in the breast cancer samples were examined by immunohistochemistry using anti-CD34. The association of MIF expression with the clinicopathological characteristics and prognosis was further analyzed using the computer software Statistical Package for the Social Sciences 13.0. RESULTS: The MIF positive expression rate of the breast cancer tissues was 29.8%, significantly higher than those of the benign tumors and normal breast tissue (P = 0.031). MIF expression rate was positively correlated with the expression of interleukin-8 (IL-8) (P= 0.014), MVD (P =0.043), and HER-2 (P=0.030). The survival rate of the patients with positive MIF expression in breast tissues was 80. 6%, not significantly different from that of the negative MIF expression group (87.1%, P = 0.171), however, the tumor-free survival rate of the MIF positive expression group was 72.2%, significantly lower than that of the MIF negative group (87.1%, P = 0.029). CONCLUSION: MIF may predict a poor prognostic factor for human breast cancer, and may be used as a novel molecular marker to predicate the progression of breast cancer. Through promoting the secretion of IL-8, MIF participates in the angiogenesis in breast cancer.